Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Salvatore Paiella

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6893-8618; OpenAlex author ID A5056335013. Sources: OpenAlex.

Their work

Papers
82 (first author 9, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
263
Papers, trials and grants by year

2015: 1 paper · 2016: 5 papers · 2017: 3 papers · 2018: 5 papers · 2019: 4 papers · 2020: 8 papers · 2021: 13 papers · 2022: 9 papers · 2023: 8 papers · 2024: 7 papers · 2025: 10 papers · 2026: 9 papers

Papers 50 of 82

  1. Presumed Intraductal Papillary Mucinous Neoplasms in Individuals at High Risk for Pancreatic Cancer. Co-author DOI 10.1001/jamanetworkopen.2026.35610↗
  2. Discovering Hereditary Risk Through Surveillance: A Prospective Genetic Analysis of Individuals With Familial Pancreatic Cancer. Co-author DOI 10.1002/ueg2.70187↗
  3. Multicenter IGoMIPS Registry-based analysis of robotic versus laparoscopic approach to left pancreatectomy for pancreatic cancer. First author DOI 10.1007/s13304-026-02831-3↗
  4. Hereditary pancreatic cancer: A proposal for surveillance from the Italian Association for the Study of the Pancreas (AISP). Last author DOI 10.1016/j.dld.2026.04.007↗
  5. AISP position statement: Standardising biological sample collection and handling for advanced diagnostics and multi-omic analyses in pancreatic cancer. Co-author DOI 10.1016/j.dld.2026.08.021↗
  6. Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2025.08.034↗
  7. Morphologic Characterization of Pancreatic Ductal Adenocarcinoma following Post-neoadjuvant Pancreatectomy and Clinical Value of Intratumor Heterogeneity. Co-author DOI 10.1097/sla.0000000000006565↗
  8. Predicting pancreatic cancer in high-risk individuals and in the general population: how long is the road yet? Co-author DOI 10.17235/reed.2026.12183/2026↗
  9. The PancreaSure Multianalyte Blood Test Performs Well at Distinguishing Early-Stage Pancreatic Ductal Adenocarcinoma from High-Risk Controls: A Retrospective S… First author DOI 10.3390/jcm15197355↗
  10. Local ablation disrupts immune evasion in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2024.217327↗
  11. Impact of exercise in patients with pancreatic cancer across different treatment phases: A systematic review. Co-author DOI 10.1016/j.critrevonc.2025.104961↗
  12. Biomarkers, omics and artificial intelligence for early detection of pancreatic cancer. Co-author DOI 10.1016/j.semcancer.2025.02.009↗
  13. Resection to Exploration Ratios and Associated Outcomes in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000006197↗
  14. Reappraising the Role of Intraoperative Neck Margin Revision in Postneoadjuvant Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Multi-institution… Co-author DOI 10.1097/sla.0000000000006322↗
  15. Carbohydrate Antigen 19-9 Delta Function for Survival Prediction in Borderline Pancreatic Cancer. A PANC-PALS Consortium International Multicenter Derivation a… Co-author DOI 10.1097/sla.0000000000006735↗
  16. Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium. Co-author DOI 10.1200/po-25-00696↗
  17. Expert Judgment Supporting a Bayesian Network to Model the Survival of Pancreatic Cancer Patients. First author DOI 10.3390/cancers17020301↗
  18. Assessment of Psychological Burden in Individuals with Hereditary Risk of Pancreatic Cancer Under Surveillance: Evaluation of Distress 3 Years After Enrollment. Co-author DOI 10.3390/cancers17183014↗
  19. Surgical and Oncological Outcomes of Minimally Invasive Left Pancreatectomy for Pancreatic Cancer: Robotic vs. Laparoscopic Approach. Co-author DOI 10.3390/curroncol32070376↗
  20. The Italian registry of families at risk for pancreatic cancer (IRFARPC): implementation and evolution of a national program for pancreatic cancer surveillance… Last author DOI 10.1007/s10689-024-00366-3↗
  21. Surveillance of Individuals at High Risk of Developing Pancreatic Cancer: A Prevalence Meta-analysis to Estimate the Rate of Low-yield Surgery. Co-author DOI 10.1097/sla.0000000000006094↗
  22. Adjuvant Therapy After Upfront Resection of Resectable Pancreatic Cancer: Patterns of Omission and Use-A Prospective Real-Life Study. Co-author DOI 10.1245/s10434-024-14951-4↗
  23. ASO Author Reflections: Adjuvant Therapy for Resectable Pancreatic Cancer in the Real World-Not as Common as One Might Think. Co-author DOI 10.1245/s10434-024-15014-4↗
  24. Outcomes of a 3-Year Prospective Surveillance in Individuals at High Risk of Pancreatic Cancer. Co-author DOI 10.14309/ajg.0000000000002546↗
  25. Cellular collusion: cracking the code of immunosuppression and chemo resistance in PDAC. Co-author DOI 10.3389/fimmu.2024.1341079↗
  26. The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals. Co-author DOI 10.6004/jnccn.2023.7097↗
  27. Immunonutrition and prehabilitation in pancreatic cancer surgery: A new concept in the era of ERAS® and neoadjuvant treatment. Co-author DOI 10.1016/j.ejso.2022.12.006↗
  28. A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic te… Co-author DOI 10.1016/j.esmoop.2023.100881↗
  29. Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells. Co-author DOI 10.1016/j.modpat.2023.100251↗
  30. A dynamic analysis of empirical survival outcomes after pancreatectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2022.11.015↗
  31. Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance. Co-author DOI 10.1158/1940-6207.capr-22-0529↗
  32. Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: A retrospective,… Co-author DOI 10.3389/fnut.2023.1065294↗
  33. Independent effect of fat-to-muscle mass ratio at bioimpedance analysis on long-term survival in patients receiving surgery for pancreatic cancer. First author DOI 10.3389/fnut.2023.1118616↗
  34. Corrigendum: Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: a r… Co-author DOI 10.3389/fnut.2023.1212436↗
  35. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detectio… Co-author DOI 10.1016/j.gie.2021.10.025↗
  36. Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals. Co-author DOI 10.1053/j.gastro.2021.10.014↗
  37. US-Guided Percutaneous Radiofrequency Ablation of Locally Advanced Pancreatic Adenocarcinoma: A 5-Year High-Volume Center Experience. Co-author DOI 10.1055/a-1178-0474↗
  38. Reassessment of the Optimal Number of Examined Lymph Nodes in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000004552↗
  39. A Pretreatment Prognostic Score to Stratify Survival in Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000004845↗
  40. Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer. Co-author DOI 10.1136/jitc-2021-003549↗
  41. Importance of Nodal Metastases Location in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: Results from a Prospective, Lymphadenectomy Protocol. Co-author DOI 10.1245/s10434-022-11417-3↗
  42. Germline Aberrations in Pancreatic Cancer: Implications for Clinical Care. Co-author DOI 10.3390/cancers14133239↗
  43. Computed tomography-based radiomic to predict resectability in locally advanced pancreatic cancer treated with chemotherapy and radiotherapy. Co-author DOI 10.4251/wjgo.v14.i3.703↗
  44. Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Co-author DOI 10.1016/j.annonc.2020.11.013↗
  45. Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcin… Co-author DOI 10.1016/j.clon.2020.06.019↗
  46. Laser Treatment of Pancreatic Cancer with Immunostimulating Interstitial Laser Thermotherapy Protocol: Safety and Feasibility Results From Two Phase 2a Studies. Co-author DOI 10.1016/j.jss.2020.10.027↗
  47. Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial. First author DOI 10.1016/j.pan.2021.06.005↗
  48. Gα15 in early onset of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-021-94150-3↗
  49. Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) Co… Co-author DOI 10.1053/j.gastro.2021.08.036↗
  50. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Co-author DOI 10.1136/jmedgenet-2020-106961↗

Closest collaborators

The 25 strongest of 263 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Roberto Salvia · 57 shared papers, 2015–2026 · strength 7.39
  2. Giuseppe Malleo · 40 shared papers, 2018–2026 · strength 5.64
  3. Claudio Bassi · 46 shared papers, 2015–2025 · strength 4.76
  4. Erica Secchettin · 18 shared papers, 2018–2026 · strength 2.75
  5. Gabriella Lionetto · 15 shared papers, 2021–2026 · strength 2.71
  6. Fabio Casciani · 13 shared papers, 2019–2026 · strength 2.58
  7. Matteo De Pastena · 13 shared papers, 2018–2026 · strength 1.91
  8. Michèle Milella · 15 shared papers, 2020–2025 · strength 1.83
  9. Massimo Falconi · 10 shared papers, 2019–2026 · strength 1.67
  10. Alessandro Esposito · 11 shared papers, 2018–2026 · strength 1.64
  11. Aldo Scarpa · 12 shared papers, 2018–2026 · strength 1.60
  12. Claudio Luchini · 9 shared papers, 2020–2026 · strength 1.50
  13. Silvia Carrara · 7 shared papers, 2019–2026 · strength 1.40
  14. Mirko D’Onofrio · 17 shared papers, 2015–2025 · strength 1.38
  15. Laura Maggino · 12 shared papers, 2018–2023 · strength 1.36
  16. Gabriele Capurso · 8 shared papers, 2019–2026 · strength 1.32
  17. Lívia Archibugi · 6 shared papers, 2024–2026 · strength 1.26
  18. Antonio Pea · 7 shared papers, 2019–2026 · strength 1.22
  19. Alessandro Zerbi · 8 shared papers, 2019–2026 · strength 1.08
  20. Isabella M. Frigerio · 12 shared papers, 2015–2026 · strength 1.06
  21. Giovanni Butturini · 12 shared papers, 2015–2026 · strength 1.04
  22. Fay Kastrinos · 7 shared papers, 2019–2026 · strength 1.00
  23. Darío Gregori · 6 shared papers, 2021–2025 · strength 0.98
  24. Randall E. Brand · 6 shared papers, 2019–2026 · strength 0.92
  25. Giovanni Marchegiani · 10 shared papers, 2018–2022 · strength 0.92

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.